Procter & Gamble Health (PGHL.BO) Earnings Analysis

Procter & Gamble Health (PGHL.BO) next reports earnings on 2026-09-02. It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 33.97.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does PGHL.BO next report earnings?

Next earnings date2026-09-02
Consensus EPS estimaten/a
Revenue estimaten/a

PGHL.BO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-2657 INRn/an/an/a
2026-02-0646.7 INR46.7 INR0%Beat
2025-08-2339.87 INRn/an/an/a
2025-05-2936.86 INRn/an/an/a
2024-11-0439.87 INRn/an/an/a
2024-08-2110.11 INRn/an/an/a

Beat rate: 1/1 (100%) over reported quarters with consensus data.

PGHL.BO valuation and analyst view

Trailing P/E33.97
Trailing EPS196.94 INR
Price / book21.17
Dividend yield3.06%
Market cap111.86B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Procter & Gamble Health (PGHL.BO)'s next earnings date?

Procter & Gamble Health is next scheduled to report on 2026-09-02.

Did PGHL.BO beat earnings last quarter?

Consensus estimate data was not available for PGHL.BO's 2026-05-26 report.

What is PGHL.BO's earnings track record?

Over the last 1 reported quarters with consensus data, PGHL.BO beat estimates 1 times (100%).

What is PGHL.BO's current P/E ratio and EPS?

PGHL.BO trades at a trailing P/E of 33.97 on trailing EPS of 196.9408176908531 INR.

What do analysts rate PGHL.BO?

PGHL.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.